9 assets in Myeloid Leukemia Associated With Down Syndrome

Therapeutic assets addressing Myeloid Leukemia Associated With Down Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cytarabine Myeloid Leukemia Associated With Down Syndrome	National Cancer Institute (NCI)	P3	BB (64)
Asparaginase Myeloid Leukemia Associated With Down Syndrome	Children's Oncology Group	P3	B (60)
Crisantaspase Myeloid Leukemia Associated With Down Syndrome	Children's Oncology Group	P3	B (60)
Daunomycin Myeloid Leukemia Associated With Down Syndrome	Children's Oncology Group	P3	B (60)
Etoposide Myeloid Leukemia Associated With Down Syndrome	Children's Oncology Group	P3	B (60)
Mitoxantrone Myeloid Leukemia Associated With Down Syndrome	Children's Oncology Group	P3	B (60)
Thioguanine Anhydrous Myeloid Leukemia Associated With Down Syndrome	Children's Oncology Group	P3	B (60)
Fludarabine Myeloid Leukemia Associated With Down Syndrome	National Cancer Institute (NCI)	P1	CC (43)
Uproleselan Myeloid Leukemia Associated With Down Syndrome	National Cancer Institute (NCI)	P1	CC (43)